Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients

Patients with non-small cell lung cancer (NSCLC) have been shown to benefit from the introduction of anti-PD1 treatment. However, not all patients experience tumor regression and durable response. The identification of a string of markers that are direct or indirect indicators of the immune system f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zizzari, Ilaria Grazia, Filippo, Alessandra Di, Scirocchi, Fabio, Di Pietro, Francesca Romana, Rahimi, Hassan, Ugolini, Alessio, Scagnoli, Simone, Vernocchi, Pamela, Del Chierico, Federica, Putignani, Lorenza, Rughetti, Aurelia, Marchetti, Paolo, Nuti, Marianna, Botticelli, Andrea, Napoletano, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712566/
https://www.ncbi.nlm.nih.gov/pubmed/33158018
http://dx.doi.org/10.3390/jpm10040208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712566/
https://www.ncbi.nlm.nih.gov/pubmed/33158018
http://dx.doi.org/10.3390/jpm10040208

Ejemplares similares